Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ADCYAP1R1 | P41586 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067512 | 0.91 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL7237622 | 0.91 | ALDH1A1 (0.63) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10323084 | 0.87 | KDM4E (0.64) | KDM4EALDH1A1ADCYAP1R1MEN1KMT2A | |
| SCHEMBL10323322 | 0.86 | KDM4E (0.62) | KDM4EALDH1A1ADCYAP1R1MEN1KMT2A | |
| SCHEMBL31192448 | 0.84 | MEN1 (0.58) | KDM4EALDH1A1MAPTADCYAP1R1MEN1 | |
| SCHEMBL3229895 | 0.84 | KDM4E (0.60) | KDM4EALDH1A1ADCYAP1R1MEN1KMT2A | |
| SCHEMBL31192445 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1ADCYAP1R1MEN1KMT2A | |
| SCHEMBL31192441 | 0.82 | KDM4E (0.64) | KDM4EALDH1A1GAAMAPTADCYAP1R1 | |
| SCHEMBL16015328 | 0.82 | MAPT (0.57) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL6584177 | 0.80 | SMPD1 (0.81) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | KDM4E 614/4885ALDH1A1 891/4885GAA 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.